Changing incidence and clinical manifestations of Clostridium difficile-associated diarrhea detected by combination of glutamate dehydrogenase and toxin assay in Northern Taiwan

Journal of Microbiology, Immunology and Infection

Volumn 45, Issue 4, 2012, Pages 287-295

  Lee, Yi Chieh ^a   Wang, Jann Tay ^a   Chen, An Chi ^a   Sheng, Wang Huei ^a   Chang, Shan Chwen ^a,b   Chen, Yee Chun ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Attributable mortality; C difficile associated diarrhea; Incidence; Taiwan

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CARBAPENEM DERIVATIVE; CEFALEXIN; CEFAZOLIN; CEFMETAZOLE; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; ERTAPENEM; GLUTAMATE DEHYDROGENASE; GLYCOPEPTIDE; IMIPENEM; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SULTAMICILLIN; TEICOPLANIN; TIMENTIN; TOXIN; UNINDEXED DRUG; VANCOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; ENZYME IMMUNOASSAY; FECES ANALYSIS; FECES CULTURE; FEMALE; HAND WASHING; HOSPITAL BED; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROSPECTIVE STUDY; TAIWAN; TEACHING HOSPITAL; TOXIN ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; BETA-LACTAMASES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DIARRHEA; FECES; FEMALE; GLUTAMATE DEHYDROGENASE; HAND DISINFECTION; HOSPITALS, TEACHING; HUMANS; INCIDENCE; MALE; METRONIDAZOLE; MIDDLE AGED; PENICILLINS; PROSPECTIVE STUDIES; TAIWAN;

EID: 84862552875     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2011.12.001     Document Type: Article

References (28)

1. Kelly C.P., Pothoulakis C., LaMont J.T. Clostridium difficile colitis. N Engl J Med 1994, 330:257-262.
2. McDonald L.C., Owings M., Jernigan D.B. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006, 12:409-415.
3. Loo V.G., Poirier L., Miller M.A., Oughton M., Libman M.D., Michaud S., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353:2442-2449.
4. Muto C.A., Pokrywka M., Shutt K., Mendelsohn A.B., Nouri K., Posey K., et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005, 26:273-280.
5. Hsu M.S., Wang J.T., Huang W.K., Liu Y.C., Chang S.C. Prevalence and clinical features of Clostridium difficile-associated diarrhea in a tertiary hospital in northern Taiwan. J Microbiol Immunol Infect 2006, 39:242-248.
6. Chung C.H., Wu C.J., Lee H.C., Yan J.J., Chang C.M., Lee N.Y., et al. Clostridium difficile infection at a medical center in southern Taiwan: incidence, clinical features and prognosis. J Microbiol Immunol Infect 2010, 43:119-125.
7. Planche T., Aghaizu A., Holliman R., Riley P., Poloniecki J., Breathnach A., et al. Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infect Dis 2008, 8:777-784.
8. Cohen S.H., Gerding D.N., Johnson S., Kelly C.P., Loo V.G., McDonald L.C., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
9. Sharp S.E., Ruden L.O., Pohl J.C., Hatcher P.A., Jayne L.M., Ivie W.M. Evaluation of the C.Diff Quik Chek Complete Assay, a new glutamate dehydrogenase and A/B toxin combination lateral flow assay for use in rapid, simple diagnosis of Clostridium difficile disease. J Clin Microbiol 2010, 48:2082-2086.
10. Chuang Y.C., Chen Y.C., Chang S.C., Sun C.C., Chang Y.Y., Chen M.L., et al. Secular trends of healthcare-associated infections at a teaching hospital in Taiwan, 1981-2007. J Hosp Infect 2010, 76:143-149.
11. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
12. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
13. Anand A., Bashey B., Mir T., Glatt A.E. Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. Am J Gastroenterol 1994, 89:519-523.
14. George W.L., Sutter V.L., Citron D., Finegold S.M. Selective and differential medium for isolation of. Clostridium difficile. J Clin Microbiol 1979, 9:214-219.
15. Allen S.D., Emery C.L., Lyerly Clostridium. Manual of clinical microbiology 2003, 835-856. American Society of Microbiology Press, Washington D.C. 8th ed. P.R. Murry, E.J. Baron, J.H. Jorgensen, M.A. Pfaller, R.H. Yolken (Eds.).
16. Goodykoontz M., Boone J.T., Link D., Lyerly D.M., Hill C.R., Henry L.R. A new rapid combination test for Clostridium difficile antigen and toxins A and B in feces - evaluation of the C. DIFF QUIK CHEK COMPLETE™ 2009, American Society for Microbiology meeting, Philadelphia, PA.
17. Vanpoucke H., De Baere T., Claeys G., Vaneechoutte M., Verschraegen G. Evaluation of six commercial assays for the rapid detection of Clostridium difficile toxin and/or antigen in stool specimens. Clin Microbiol Infect 2001, 7:55-64.
18. Ananthakrishnan A.N. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 2011, 8:17-26.
19. Chandler R.E., Hedberg K., Cieslak P.R. Clostridium difficile-associated disease in Oregon: increasing incidence and hospital-level risk factors. Infect Control Hosp Epidemiol 2007, 28:116-122.
20. Impallomeni M., Galletly N.P., Wort S.J., Starr J.M., Rogers T.R. Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime. BMJ 1995, 311:1345-1346.
21. Climo M.W., Israel D.S., Wong E.S., Williams D., Coudron P., Markowitz S.M. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med 1998, 128:989-995.
22. Baines S.D., Freeman J., Wilcox M.H. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. J Antimicrob Chemother 2005, 55:974-982.
23. Vernaz N., Sax H., Pittet D., Bonnabry P., Schrenzel J., Harbarth S. Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and Clostridium difficile. J Antimicrob Chemother 2008, 62:601-607.
24. Kaier K., Hagist C., Frank U., Conrad A., Meyer E. Two-time series analyses of the impact of antibiotic consumption and alcohol-based hand disinfection on the incidences of nosocomial methicillin-resistant Staphylococcus aureus infection and Clostridium difficile infection. Infect Control Hosp Epidemiol 2009, 30:346-353.
25. Dubberke E.R., Butler A.M., Reske K.A., Agniel D., Olsen M.A., D'Angelo G. Attributable outcomes of endemic Clostridium difficile associated disease in nonsurgical patients. Emerg Infect Dis 2008, 14:1031-1038.
26. Lin Y.C., Huang Y.T., Tsai P.J., Lee T.F., Lee N.Y., Liao C.H., et al. Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in Taiwan. Antimicrob Agents Chemother 2011, 55:1701-1705.
27. Reddymasu S., Sheth A., Banks D.E. Is fecal leukocyte test a good predictor of Clostridium difficile associated diarrhea?. Ann Clin Microbiol Antimicrob 2006, 19:5-9.
28. Thielman N.M., Guerrant R.L. Clostridium difficile and its toxins. Bacterial toxins and virulence factors in disease 1995, 327-366. Marcel Dekker, New York. J. Moss, B. Iglewski, M. Vaughn, A.T. Tue (Eds.).